FDA approves two new diabetes drugs

FDA has cleared two new drugs, insulin degludec injection (Tresiba—Novo Nordisk) and insulin degludec/insulin aspart injection (Ryzodeg 70/30—Novo Nordisk), for adults with diabetes. Insulin degludec injection, a long-acting insulin analog, was approved to improve glycemic control in adults with type 1 and type 2 diabetes.

FDA has cleared two new drugs, insulin degludec injection (Tresiba—Novo Nordisk) and insulin degludec/insulin aspart injection (Ryzodeg 70/30—Novo Nordisk), for adults with diabetes. Insulin degludec injection, a long-acting insulin analog, was approved to improve glycemic control in adults with type 1 and type 2 diabetes. The drug is administered subcutaneously once a day. Insulin degludec/insulin aspart injection, a combination of a long-acting insulin analog and a rapid-acting insulin analog, was approved to improve glycemic control in adults with type 2 diabetes. The most frequently adverse events reported with the two drugs in clinical trials were hypoglycemia, allergic reactions, injection site reactions, pitting at the injection site, itching, rash, edema, and weight gain. FDA notes that neither drug should be used in adults who have diabetic ketoacidosis.